Sanofi acquires rights to develop and commercialize Aficamten in Greater China
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia
Cenexi is committed to working closely with the ANSM to address the observations
The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”
JCI accreditation is recognized globally
The TPE Tourniquet and TPE Esmark Bandages are renowned for their single-use design,
Subscribe To Our Newsletter & Stay Updated